Author/Creator: Wagener, Jeffrey S. - British Library Electronic Legal Deposit Catalogue-Journal Issues and Articles Search Results

Author/Creator Wagener, Jeffrey S.

1. Clinical use of tobramycin inhalation solution (TOBI®) shows sustained improvement in FEV1 in cystic fibrosis. Issue 6 (9th September 2013)

Authors:: Konstan, Michael W.; Wagener, Jeffrey S.; Pasta, David J.; Millar, Stefanie J.; Morgan, Wayne J.
Journal:: Pediatric pulmonology
Issue:: Volume 49:Issue 6(2014:Jun.)
Page Start:: 529
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

2. Comparison of FEV1 reference equations for evaluating a cystic fibrosis therapeutic intervention. Issue 8 (3rd July 2017)

Authors:: Konstan, Michael W.; Wagener, Jeffrey S.; VanDevanter, Donald R.; Pasta, David J.; Millar, Stefanie J.; Morgan, Wayne J.
Journal:: Pediatric pulmonology
Issue:: Volume 52:Issue 8(2017)
Page Start:: 1013
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

3. Epidemiologic Study of Cystic Fibrosis: 25 years of observational research. Issue 5 (12th January 2021)

Authors:: Konstan, Michael W.; Pasta, David J.; VanDevanter, Donald R.; Wagener, Jeffrey S.; Morgan, Wayne J.
Journal:: Pediatric pulmonology
Issue:: Volume 56:Issue 5(2021)
Page Start:: 823
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

4. Frequency and costs of pulmonary exacerbations in patients with cystic fibrosis in the United States. (3rd April 2017)

Authors:: Rubin, Jaime L.; Thayer, Sarah; Watkins, Angela; Wagener, Jeffrey S.; Hodgkins, Paul S.; Schechter, Michael S.
Journal:: Current medical research and opinion
Issue:: Volume 33:Number 4(2017)
Page Start:: 667
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

5. Healthcare resource utilization associated with ivacaftor use in patients with cystic fibrosis. (1st September 2016)

Authors:: Suthoff, Ellison D.; Bonafede, Mac; Limone, Brendan; O'Callaghan, Lasair; Sawicki, Gregory S.; Wagener, Jeffrey S.
Journal:: Journal of medical economics
Issue:: Volume 19:Number 9(2016)
Page Start:: 845
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

6. Lung function changes before and after pulmonary exacerbation antimicrobial treatment in cystic fibrosis. Issue 3 (20th November 2019)

Authors:: Wagener, Jeffrey S.; VanDevanter, Donald R.; Konstan, Michael W.; Pasta, David J.; Millar, Stefanie J.; Morgan, Wayne J.
Journal:: Pediatric pulmonology
Issue:: Volume 55:Issue 3(2020)
Page Start:: 828
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

7. Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis12. Issue 7 (8th August 2012)

Authors:: Wagener, Jeffrey S.; Rasouliyan, Lawrence; VanDevanter, Donald R.; Pasta, David J.; Regelmann, Warren E.; Morgan, Wayne J.; Konstan, Michael W.
Journal:: Pediatric pulmonology
Issue:: Volume 48:Issue 7(2013:Jul.)
Page Start:: 666
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

8. Pulmonary exacerbations in cystic fibrosis: Young children with characteristic signs and symptoms12. Issue 7 (4th September 2012)

Authors:: Regelmann, Warren E.; Schechter, Michael S.; Wagener, Jeffrey S.; Morgan, Wayne J.; Pasta, David J.; Elkin, Eric P.; Konstan, Michael W.
Journal:: Pediatric pulmonology
Issue:: Volume 48:Issue 7(2013:Jul.)
Page Start:: 649
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗